axicabtagene ciloleucel

AXP000014.1 · CAR-T cell therapy

Platform
autologous CAR-T
Targets
CD19
Originator
National Cancer Institute
Sponsor
Kite Pharma (Gilead Sciences)

Names

NameTypeSource
axicabtagene ciloleucelpreferred name, INNcurator, ncit
Yescartabrandncit
KTE-C19codencit
axi-celsynonymncit

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
retrovirus
Replication
non replicating
Modifications
replication-incompetent retroviral vector; murine anti-CD19 scFv with CD28 and CD3 zeta domains. The label does not name the retrovirus, so `virus` says only retrovirus
Transgenes
anti-CD19 chimeric antigen receptor
Route
ex vivo, intravenous
Carrier
autologous T cells
Source
evidence

Cross-references

NCI Thesaurus
C120309
Wikidata
Q30314851
FDA UNII
U2I8T43Y7R

Approvals

AgencyRegionDateStatusBrandIndicationSource
FDAUS2017-10-18approvedYescartaAdults with large B-cell lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy; after two or more lines; and relapsed or refractory follicular lymphoma after two or more lines (accelerated approval). Not for primary CNS lymphomasource
EMAEU2018-08-23approvedYescartaAdults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma refractory to or relapsing within 12 months of first-line chemoimmunotherapy; relapsed or refractory DLBCL or primary mediastinal large B-cell lymphoma after two or more lines; relapsed or refractory follicular lymphoma after three or more linessource
PMDAJP2021-01-22approvedYescartaRelapsed or refractory large B-cell lymphoma: diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma and high-grade B-cell lymphomasource

Clinical trials (58)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06902012Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell LymphomaRecruitingPhase 1/22027-022028-0215Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07892027Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingPhase 22026-11-012028-05-0126Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Mantle Cell Lymphoma
NCT07932730Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/22026-112028-0512Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma
NCT07725406Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaRecruitingPhase 12026-112028-08-0132Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed or Refractory Multiple Myeloma (MM)
NCT07763210Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingPhase 22026-09-252028-03-0159Non-hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma
NCT07606937A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.RecruitingEarly phase 12026-06-122026-11-3012Relapsed/Refractory Large B-cell Lymphoma
NCT07479797Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyActive not recruitingPhase 32026-05-222031-05550Relapsed or Refractory Large B-cell Lymphoma
NCT07538635CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.RecruitingPhase 22026-04-202028-02-2920High-risk R/R LBCL
NCT07052305NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell LymphomaRecruitingPhase 12026-03-122027-11-3024Large B-cell Lymphoma
NCT07326371Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruitingPhase 22026-032027-0724DLBCL - Diffuse Large B Cell Lymphoma
NCT07042438Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T CellsRecruitingPhase 22026-02-112029-01-2356Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruitingPhase 32026-01-122029-12400Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed; Large B-cell Lymphoma; Lymphoma, B-Cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma Refractory/ Relapsed; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma
NCT06935136Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell LymphomaNot yet recruiting2025-04-302026-10-0960CAR-T Cell Therapy; High-risk Large B-cell Lymphoma (LBCL)
NCT06912529Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell LymphomaTerminatedPhase 22025-03-132025-07-251B-cell Lymphoma Recurrent; B-cell Lymphoma Refractory
NCT05077527Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin LymphomaRecruitingPhase 12025-02-132028-01-3120AIDS-Related Diffuse Large B-cell Lymphoma; AIDS-Related Non-Hodgkin Lymphoma; HIV Infection; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 3b Follicular Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Grade 3b Follicular Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed B-Cell Non-Hodgkin Lymphoma
NCT06826118Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular LymphomaRecruitingPhase 22025-02-082026-12-3130Follicular Lymphoma; Lymphoma; Refractory Lymphoma
NCT07254754Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaRecruitingPhase 22024-11-202027-01-3145DIFFUSE LARGE B-CELL LYMPHOMA
NCT06609304Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaRecruitingPhase 42024-09-302026-08-3120Lymphoma, B-Cell
NCT06550141Emapalumab Prevention of CAR-T Cell Associated ToxicitiesRecruitingPhase 22024-09-182027-08-0128Diffuse Large B Cell Lymphoma; Follicular Lymphoma; High-grade B-cell Lymphoma; Large B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non-Hodgkin Lymphoma
NCT06213311A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 22024-05-072027-07-3140B Cell Lymphoma
NCT06218602Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.RecruitingPhase 22024-02-192028-08-0140Lymphoma
NCT06043323A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular LymphomaRecruitingPhase 22024-01-082028-09-0120Follicular Lymphoma
NCT06104592Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLRecruitingPhase 22023-11-082026-1227Large B-cell Lymphoma; Relapsed Non-Hodgkin Lymphoma
NCT05950802Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With YescartaRecruitingPhase 12023-07-142027-0940DLBCL - Diffuse Large B Cell Lymphoma
NCT05633615Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingPhase 22023-06-122030-06-30396Diffuse Large B-Cell Lymphoma; Grade 3b Follicular Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Follic Lymph to Diff Large B-Cell Lymphoma; Transformed Marg Zone Lymph to Diff Large B-Cell Lymphoma
NCT05794958Axicabtagene Ciloleucel Reinfusion(Axi-Cel-2) in Relapsed/Refractory 2nd Line High-Risk NHLActive not recruitingPhase 12023-05-232026-04-1327Large B-cell Lymphoma; Non-Hodgkin Lymphoma
NCT05757219Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell TherapyRecruitingPhase 22023-05-192027-0227Diffuse Large B Cell Lymphoma
NCT05800067Axi-cel Retreatment in Relapsed/Refractory LBCLUnknown2023-03-042024-12-3132CAR-T Retreatment
NCT05605899Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell LymphomaActive not recruitingPhase 32023-02-102031-03300High-risk Large B-cell Lymphoma (LBCL)
NCT05641428Comparison of Point-of-care Produced CAR T-cell With Commercial CAR T-cells in Patients With R/R LBCLActive not recruitingPhase 22022-10-182027-06340DLBCL - Diffuse Large B Cell Lymphoma; NHL
NCT05371093Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular LymphomaActive not recruitingPhase 32022-09-222030-10231Relapsed/Refractory Follicular Lymphoma
NCT05459571Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell LymphomaCompletedPhase 22022-08-092025-11-2435Relapsed or Refractory Large B-cell Lymphoma
NCT05370547Chidamide Bridging for CAR-T TherapyUnknownPhase 1/22022-05-252024-06-30120Non Hodgkin's Lymphoma
NCT05041309Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitation2021-12-152040-121500Autoimmune Diseases; Solid and Hematological Malignancies
NCT05108805Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient SettingCompletedPhase 42021-12-022023-12-0825Diffuse Large B-cell Lymphoma; Large B-cell Lymphoma
NCT05075603Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyCompletedPhase 12021-07-292024-12-1817DLBCL Arising From Follicular Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B-cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma
NCT04855253Ph I/II Study of E7777 Prior to CAR-T for R/R LBCLSuspendedPhase 1/22021-06-092027-0930DLBCL; DLBCL Arising From Follicular Lymphoma; Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma
NCT04531046Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell TransplantationActive not recruitingPhase 22021-03-102022-04-1962B-Cell Lymphoma Refractory; B-cell Lymphoma Recurrent
NCT05349201CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)Completed2020-12-092021-05-28273Acute Lymphoblastic Leukemia (ALL); Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04608487Axi-cel in CNS LymphomaActive not recruitingPhase 12020-12-042025-06-1418Lymphoma; Lymphoma Cns
NCT04257578Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell LymphomaActive not recruitingPhase 1/22020-12-022025-08-0723B-Cell Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; High Grade B-Cell Lymphoma; Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
NCT04150913A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated NeurotoxicityCompletedPhase 22020-10-012023-10-3015Cytokine Release Syndrome; Neurotoxicity; Neurotoxicity Syndromes; Non Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma; Relapsed Non Hodgkin Lymphoma
NCT04432506Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell LymphomaCompletedPhase 22020-07-272024-05-2822Hematopoietic and Lymphoid Cell Neoplasm; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
NCT04314843Study of Lenzilumab and Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell LymphomaTerminatedPhase 12020-05-262021-03-166Relapsed/Refractory Large B-cell Lymphoma
NCT04319237Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported OutcomesCompleted2020-03-102023-07-1460Diffuse Large B Cell Lymphoma; Transformed Lymphoma
NCT04205838Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell LymphomaTerminatedPhase 22020-03-042026-02-1923Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; High Grade B-Cell Lymphoma; Progressive Disease; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent High Grade B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory High Grade B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
NCT04071366A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell TherapyCompletedPhase 22020-02-072023-02-23112Cytokine Release Syndrome
NCT04002401Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell LymphomaCompletedPhase 22019-11-052023-01-3027Refractory Large B-cell Lymphoma
NCT03761056Study to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell LymphomaCompletedPhase 22019-01-292023-10-1242B-cell Lymphoma
NCT03642626MT2017-45: CAR-T Cell Therapy for Heme MalignanciesActive not recruitingPhase 22018-12-182024-02-09150Acute Lymphoblastic Leukemia; Large B-cell Lymphoma
NCT03704298Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell LymphomaTerminatedPhase 12018-11-202021-05-0715Relapsed/Refractory Large B-cell Lymphoma
NCT03391466Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedPhase 32018-01-252021-03-18359Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
NCT03105336A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin LymphomaCompletedPhase 22017-06-062024-12-20159Follicular Lymphoma; Indolent Non-Hodgkin Lymphoma; Marginal Zone Lymphoma
NCT02926833Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedPhase 1/22016-09-292023-01-1237Refractory Diffuse Large B Cell Lymphoma
NCT02601313Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)CompletedPhase 22015-11-092023-09-22105Relapsed/Refractory Mantle Cell Lymphoma
NCT02348216Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedPhase 1/22015-04-212023-07-27307High Grade B-cell Lymphoma (HGBCL); Primary Mediastinal B-cell Lymphoma (PMBCL); Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL)
NCT05776160Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene CiloleucelAvailableFollicular Lymphoma; Large B-cell Lymphoma
NCT03153462Axicabtagene Ciloleucel Expanded Access StudyApproved for marketingRelapsed/Refractory Diffuse Large B Cell Lymphoma; Relapsed/Refractory High-Grade B-Cell Lymphoma; Relapsed/Refractory Primary Mediastinal B Cell Lymphoma; Relapsed/Refractory Transformed Follicular Lymphoma
Unconfirmed matches (2)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT06271369Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.Completed2022-08-112023-02-15613Diffuse Large B-cell Lymphomaname in title: axi-cel
NCT04514029Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-CelActive not recruitingEarly phase 12020-08-062023-11-0337Lymphomaname in title: axi-cel

Recent changes

SeenTrialChangeDetailTitle
2026-11-12NCT05459571results postedStudy of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
2026-11-12NCT07932730new trialDisulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical papers

PubMedTitleJournalYearLinked by
PMID 41062320Persistent Unilateral Pleural Effusion with Chimeric Antigen Receptor T-cell Infiltration in Primary Mediastinal Large B-cell Lymphoma.Internal medicine (Tokyo, Japan)2026name in abstract: axicabtagene ciloleucel
PMID 41076192CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41160777Brexucabtagene autoleucel for BTKi-naive relapsed/refractory mantle cell lymphoma: primary analysis of ZUMA-2 cohort 3.Blood2026cited by trial NCT02601313
PMID 41231109Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research2026name in title: axicabtagene ciloleucel
PMID 41437832Locally manufactured versus commercial CAR T therapy for large B-cell lymphoma: a multicenter propensity scorematched analysis.Haematologica2026name in abstract: axicabtagene ciloleucel
PMID 41492094Axicabtagene ciloleucel in combination with rituximab for refractory large B cell lymphoma: the phase 2, single-arm ZUMA-14 trial.Nature cancer2026cited by trial NCT04002401
PMID 41508112Multicenter real-life evaluation of the Post-CAR prognostic index for patients with large B-cell lymphoma after CAR-T failure.Journal of hematology & oncology2026name in abstract: axicabtagene ciloleucel
PMID 41512176Health-related quality of life after second-line axi-cel in transplant-ineligible patients with large B-cell lymphoma.Blood advances2026cited by trial NCT04531046
PMID 41641106Case Report: CD19 CAR-T therapy induces durable remission in a pediatric patient with TP53-mutated, refractory Burkitt lymphoma: a 30-month follow-up.Frontiers in oncology2026name in abstract: axicabtagene ciloleucel
PMID 41686452Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.Blood advances2026cited by trial NCT02601313
PMID 41716106[Efficacy of axi-cel in a patient with high-grade large B-cell lymphoma refractory to first-line therapy: importance of early identification and referral of the patient potentially eligible for CAR-T in defining the patient's outcome].Recenti progressi in medicina2026name in title: axi-cel
PMID 41716107[CAR-T cell immunotherapy in early relapse after introduction chemoimmunotherapy].Recenti progressi in medicina2026name in abstract: axi-cel
PMID 41716108[Beyond comorbidities: CAR-T as a safe and effective option in frail patients with second-line DLBCL].Recenti progressi in medicina2026name in abstract: axicabtagene ciloleucel
PMID 41716109[Refractory DLBCL to a polatuzumab-containing regimen: efficacy of CAR-T therapy in second line with radiotherapy bridging].Recenti progressi in medicina2026name in abstract: axicabtagene ciloleucel
PMID 41716111[CAR-T: an effective option in primary refractory patients].Recenti progressi in medicina2026name in abstract: axi-cel
PMID 41747197Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study.Blood advances2026name in abstract: axicabtagene ciloleucel
PMID 41763314Outpatient Versus Inpatient Axicabtagene Ciloleucel CAR T-Cell Therapy in Non-Hodgkin's Lymphoma: Insights From A US Multicenter Transplant and Cellular Therapy Network.Transplantation and cellular therapy2026name in title: axicabtagene ciloleucel
PMID 41765136Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41777880Non-ICANS neurotoxicities CD19-directed CAR T-cell therapy and the emergence of movement and neurocognitive treatment-emergent adverse events: a case report.Frontiers in immunology2026name in abstract: axicabtagene ciloleucel
PMID 41856668Risk Assessment in Large B-Cell Lymphoma Using Metabolic Tumor Volume: Real-World Data from a Multicenter Cohort of Patients Undergoing CAR T-Cell Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2026name in abstract: axicabtagene ciloleucel
PMID 41993175Case Report: Transverse myelitis following CAR-T cell therapy for post-transplant lymphoproliferative disorder.Frontiers in immunology2026name in abstract: axicabtagene ciloleucel
PMID 42036693Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.Journal of hematology & oncology2026cited by trial NCT02601313
PMID 42134094Real-world outcomes of Axicabtagene Ciloleucel CAR-T therapy in large B-cell lymphoma: a single-center observational study.Cytotherapy2026name in title: axicabtagene ciloleucel
PMID 42178058Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies.Transplantation and cellular therapy2026name in abstract: axi-cel
PMID 42285114Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective study.The Lancet. Haematology2026name in abstract: axicabtagene ciloleucel
PMID 42285354Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 42341321Late cytopenia after CD19 chimeric antigen receptor T-cell therapy in large B-cell lymphoma: a Cell Therapy Consortium analysis.Blood advances2026name in abstract: axicabtagene ciloleucel
PMID 42745632Plain language summary of the ZUMA-5 study of axicabtagene ciloleucel for people with relapsed or refractory slow-growing non-Hodgkin lymphoma.Future oncology (London, England)2026cited by trial NCT03105336
PMID 42770797A patient's experience with follicular lymphoma from diagnosis to cure: the life-changing impact of CAR T-cell therapy.Future oncology (London, England)2026name in abstract: axicabtagene ciloleucel
PMID 42816413Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy.Journal of clinical and experimental hematopathology : JCEH2026name in abstract: axicabtagene ciloleucel
PMID 42877902Pseudoprogression after Axi-cel in Primary Refractory PMBCL following Failed Bridging: Case Report and Management Considerations.Case reports in oncology2026name in title: axi-cel
PMID 42898883Irreversible paraplegia due to transverse myelitis as a rare complication of CAR T-cell therapy in a patient with B-cell lymphoma.Postepy psychiatrii neurologii2026name in abstract: axicabtagene ciloleucel
PMID 42909844Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States.Advances in therapy2026cited by trial NCT03391466
PMID 42930590Baseline Tumor Transcriptional Features and Event-Free Survival After Anti-CD19 CAR T-Cell Therapy with Axicabtagene Ciloleucel in Large B-Cell Lymphoma: An Exploratory Reanalysis of the Randomized ZUMA-7 Trial.Medical sciences (Basel, Switzerland)2026name in title: axicabtagene ciloleucel
PMID 39425562Severe cytopenia after chimeric antigen receptor-T cell driven by large granular lymphocytes and responsive to steroids.British journal of haematology2025name in abstract: axicabtagene ciloleucel
PMID 39441941Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.Blood2025cited by trial NCT06218602
PMID 39840879[Pseudoprogression after CAR-T cell therapy: friend or foe?].Recenti progressi in medicina2025name in abstract: axicabtagene ciloleucel
PMID 39840881[CAR-T therapy in elderly patients with relapsed/refractory diffuse large B-cell lymphoma. Clinical case of the San Martino Hospital in Genoa].Recenti progressi in medicina2025name in abstract: axicabtagene ciloleucel
PMID 39928957Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.Blood advances2025cited by trial NCT04150913
PMID 39931889[The first Italian patient affected by diffuse large B-cell lymphoma treated with axi-cel in the second line: innovation and tradition].Recenti progressi in medicina2025name in title: axi-cel
PMID 39931890[Experience of therapy with axi-cel CAR-T in an elderly patient suffering from double expressor DLBCL in an advanced stage and refractory to first-line chemoimmunotherapy].Recenti progressi in medicina2025name in title: axi-cel
PMID 39931891[Successfully treatment with axicabtagene ciloleucel of a female patient with an early relapsed diffuse large B-cell lymphoma].Recenti progressi in medicina2025name in title: axicabtagene ciloleucel
PMID 39938007Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma.Blood2025name in abstract: axicabtagene ciloleucel
PMID 39938019Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study.Blood2025cited by trial NCT03761056
PMID 39998830Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.JAMA network open2025name in abstract: axicabtagene ciloleucel
PMID 40025178Chimeric antigen receptor T cell therapy in octogenarians with B cell lymphoma: a real-world US multicenter collaborative study.Bone marrow transplantation2025name in abstract: axicabtagene ciloleucel
PMID 40090005Itacitinib for the prevention of IEC therapy-associated CRS: results from the 2-part phase 2 INCB 39110-211 study.Blood2025cited by trial NCT04071366
PMID 40128603Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial.Bone marrow transplantation2025name in title: axicabtagene ciloleucel
PMID 40203192Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study.Blood advances2025name in abstract: axicabtagene ciloleucel
PMID 40246539Semiquantitative PET Parameters Refine Prognosis in CAR T-Treated Lymphoma After 1 and 3 Months: A Prospective Single-Center Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine2025name in abstract: axicabtagene ciloleucel
PMID 40347097Efficacy of Axicabtagene Ciloleucel Compared to Historical Treatments for Relapsed/Refractory Diffuse Large B-Cell Lymphoma of Asian Descent: A Matching Adjusted Indirect Comparison of ZUMA-1 vs REAL-TREND.Hematological oncology2025name in title: axicabtagene ciloleucel
PMID 40438977CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study.Haematologica2025name in abstract: axicabtagene ciloleucel
PMID 40536814Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma.The Journal of clinical investigation2025cited by trial NCT03105336
PMID 40589238Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experience.British journal of haematology2025name in abstract: axi-cel
PMID 40708270Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma.Leukemia & lymphoma2025name in title: axicabtagene ciloleucel
PMID 40759437Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.Journal for immunotherapy of cancer2025name in abstract: axicabtagene ciloleucel
PMID 40815804Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma.Blood advances2025name in abstract: axicabtagene ciloleucel
PMID 40902085An AI model classifies risks of early relapse post-CAR T-cell therapy in a multicenter real-world population with DLBCL.Blood advances2025name in abstract: axicabtagene ciloleucel
PMID 40948517Outpatient axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma: ZUMA-24 primary analysis.American journal of cancer research2025cited by trial NCT05459571
PMID 40954138Use of Dasatinib for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome After Axicabtagene Ciloleucel Infusion: A Case Report.European journal of haematology2025name in title: axicabtagene ciloleucel
PMID 41100801Five-Year Follow-Up Analysis of ZUMA-5: Axicabtagene Ciloleucel in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2025cited by trial NCT03105336
PMID 41126598The French Experience of Pharmacists and CAR T-Cells: A Study of the French Society of Oncology Pharmacy (SFPO).Hematological oncology2025name in abstract: axi-cel
PMID 41170601Liquid biopsy-directed therapy in primary bone lymphoma: venetoclax-Pola-R-CHP and CAR-T achieve molecular remission: a case report.Current medical research and opinion2025name in abstract: axicabtagene ciloleucel
PMID 41306534Case Report: Rare adverse events following CAR-T therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.Frontiers in oncology2025name in abstract: axicabtagene ciloleucel
PMID 41583270Cytomegalovirus Lymphadenitis After Anti-CD19 Chimeric Antigen Receptor T-cell (CAR-T): An Underappreciated Etiology of Hypermetabolic Lymphadenopathy in the Post-CAR-T Setting.Cureus2025name in abstract: axicabtagene ciloleucel
PMID 37879047Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).Blood2024name in title: axicabtagene ciloleucel
PMID 37973893Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.Bone marrow transplantation2024name in abstract: axicabtagene ciloleucel
PMID 38051550Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.Blood advances2024name in title: axicabtagene ciloleucel
PMID 38114616Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy.European journal of nuclear medicine and molecular imaging2024name in abstract: axicabtagene ciloleucel
PMID 38196817Exacerbations of Persistent Neurotoxicity following Axicabtagene Ciloleucel in a Patient with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Case Report.Case reports in oncology2024name in title: axicabtagene ciloleucel
PMID 38315832Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.Blood advances2024name in title: axicabtagene ciloleucel
PMID 38359407Monocytes in leukapheresis products affect the outcome of CD19-targeted CAR T-cell therapy in patients with lymphoma.Blood advances2024name in abstract: axicabtagene ciloleucel
PMID 38459167Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.Leukemia2024name in title: axicabtagene ciloleucel
PMID 38504387Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.American journal of hematology2024name in title: axicabtagene ciloleucel
PMID 38552193Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2024name in abstract: axicabtagene ciloleucel
PMID 38557775Axicabtagene ciloleucel vs standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.Blood2024name in title: axicabtagene ciloleucel
PMID 38594876Outcome and feasibility of radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T in the UK.British journal of haematology2024name in abstract: axicabtagene ciloleucel
PMID 38635762Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity.Blood2024cited by trial NCT02348216
PMID 38703571Rapid response in relapsed follicular lymphoma to novel anti-CD19 CAR-T therapy with pseudo-progression and cytomegalovirus infection: A case report.International immunopharmacology2024name in abstract: Yescarta
PMID 38865660Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy.The New England journal of medicine2024name in abstract: axicabtagene ciloleucel
PMID 38953781A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.Blood cancer discovery2024name in title: axicabtagene ciloleucel
PMID 38982730Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma.Journal of cutaneous pathology2024name in abstract: axicabtagene ciloleucel
PMID 39069076Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO.Transplantation and cellular therapy2024name in abstract: axicabtagene ciloleucel
PMID 39240498Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's Lymphoma.Clinical pharmacokinetics2024cited by trial NCT02348216
PMID 39266425[Real-life evaluation of the care pathway of patients eligible for axicabtagene ciloleucel treatment: Analysis of a multicenter retrospective cohort (IMPA-CT study)].Bulletin du cancer2024name in title: axicabtagene ciloleucel
PMID 39396632Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.Transplantation and cellular therapy2024name in abstract: axicabtagene ciloleucel
PMID 39417342Hemophagocytic lymphohistiocytosis in a patient with Epstein-Barr virus-positive diffuse large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.Immunotherapy2024name in abstract: axicabtagene ciloleucel
PMID 39580601EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy.Scientific reports2024name in abstract: axicabtagene ciloleucel
PMID 39717043Cytokine Release Syndrome After CAR T-Cell Therapy in a 35-Year-Old Patient With Pneumocystis jiroveci Pneumonia and Cytomegalovirus Viremia.Case reports in medicine2024name in abstract: axicabtagene ciloleucel
PMID 35658525Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2023cited by trial NCT02601313
PMID 36399286A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis.International journal of hematology2023name in title: axicabtagene ciloleucel
PMID 36508286Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.Blood advances2023name in abstract: axicabtagene ciloleucel
PMID 36646322Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.Transplantation and cellular therapy2023name in title: axicabtagene ciloleucel
PMID 36821768Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.Blood2023cited by trial NCT02348216
PMID 36950962Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.Immunotherapy2023name in abstract: axicabtagene ciloleucel
PMID 36964939Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.European journal of haematology2023name in abstract: axicabtagene ciloleucel
PMID 36999993Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research2023name in title: axicabtagene ciloleucel
PMID 37126659Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.Blood advances2023name in title: axicabtagene ciloleucel
PMID 37272527Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.The New England journal of medicine2023name in title: axicabtagene ciloleucel
PMID 37399456A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.Blood advances2023name in abstract: axicabtagene ciloleucel
PMID 37400640CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results.Nature medicine2023name in abstract: axicabtagene ciloleucel
PMID 37522731Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.Blood advances2023name in title: axi-cel
PMID 37527011Axicabtagene Ciloleucel in Combination with the 4-1BB Agonist Utomilumab in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Phase 1 Results from ZUMA-11.Clinical cancer research : an official journal of the American Association for Cancer Research2023name in title: axicabtagene ciloleucel
PMID 37625977Accelerated cortical atrophy and hypometabolism following axicabtagene ciloleucel treatment: A case report.Revue neurologique2023name in title: axicabtagene ciloleucel
PMID 37659694Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.Transplantation and cellular therapy2023name in abstract: axi-cel
PMID 37710005Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial.Nature medicine2023cited by trial NCT04531046
PMID 37841271Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis.Frontiers in immunology2023name in abstract: axicabtagene ciloleucel
PMID 37842456Anti-CD19 Chimeric Antigen Receptor T Cell Therapy With Tisagenlecleucel for Secondary Central Nervous System Lymphoma: A Case Series.Cureus2023name in abstract: axicabtagene ciloleucel
PMID 37946255Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.Journal of hematology & oncology2023name in abstract: axi-cel
PMID 38022532Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models.Frontiers in immunology2023cited by trial NCT04855253
PMID 34233446Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.Haematologica2022name in abstract: axicabtagene ciloleucel
PMID 34259446Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.Critical care medicine2022name in abstract: axicabtagene ciloleucel
PMID 34599413Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.International journal of clinical oncology2022name in title: axicabtagene ciloleucel
PMID 34727319Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse large B-cell lymphoma in Chinese patients.Frontiers of medicine2022name in abstract: axicabtagene ciloleucel
PMID 34891224Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.The New England journal of medicine2022name in title: axicabtagene ciloleucel
PMID 34895487Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.The Lancet. Oncology2022name in title: axicabtagene ciloleucel
PMID 349226482021 ASH annual meeting.The Lancet. Haematology2022cited by trial NCT03391466
PMID 34950390Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy.The Neurohospitalist2022name in abstract: axicabtagene ciloleucel
PMID 35114155The role of conferences in tackling inequalities.The Lancet. Haematology2022cited by trial NCT03391466
PMID 35314842Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.Nature medicine2022name in title: axicabtagene ciloleucel
PMID 35403693FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma.The oncologist2022name in title: axicabtagene ciloleucel
PMID 35404315Axicabtagene Ciloleucel in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience.Journal of immunotherapy (Hagerstown, Md. : 1997)2022name in title: axicabtagene ciloleucel
PMID 35839452Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma.Blood2022name in title: axicabtagene ciloleucel
PMID 35850429Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.Transplantation and cellular therapy2022name in title: axicabtagene ciloleucel
PMID 36116729Late haemophagocytic lymphohistiocytosis in a patient treated with Axicabtagene ciloleucel.Transplant immunology2022name in title: axicabtagene ciloleucel
PMID 36648879It Is in the Eye of the Beholder: Ocular Ultrasound Enhanced Monitoring of Neurotoxicity after CAR-T Cell Therapy.Hematology reports2022name in abstract: axicabtagene ciloleucel
PMID 33288485Ofatumumab, Etoposide, and Cytarabine Intensive Mobilization Regimen in Patients with High-risk Relapsed/Refractory Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation.Clinical lymphoma, myeloma & leukemia2021cited by trial NCT03391466
PMID 33334730A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.Cancer discovery2021cited by trial NCT02348216
PMID 33385585A Real-Time Quantitative PCR Targeting the Viral Vector for the Monitoring of Patients Treated with Axicabtagene Ciloleucel.The Journal of molecular diagnostics : JMD2021name in title: axicabtagene ciloleucel
PMID 33509115Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.BMC infectious diseases2021name in abstract: axicabtagene ciloleucel
PMID 33608749Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.European journal of clinical pharmacology2021name in abstract: axicabtagene ciloleucel
PMID 33623881Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma.HemaSphere2021name in title: axicabtagene ciloleucel
PMID 33641257Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel.Cancer medicine2021name in title: axicabtagene ciloleucel
PMID 34041526CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel.Blood2021name in title: axicabtagene ciloleucel
PMID 34133196Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2021name in title: axicabtagene ciloleucel
PMID 34166502CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.Blood2021name in abstract: axicabtagene ciloleucel
PMID 34265479Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.Transplantation and cellular therapy2021name in abstract: axicabtagene ciloleucel
PMID 34296427Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.British journal of haematology2021cited by trial NCT02348216
PMID 34310745Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials.American journal of hematology2021cited by trial NCT02348216
PMID 34336692Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report.Frontiers in oncology2021name in abstract: axicabtagene ciloleucel
PMID 34493319Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.Journal of hematology & oncology2021cited by trial NCT02348216
PMID 34496024Fatal late-onset CAR T-cell-mediated encephalitis after axicabtagene-ciloleucel in a patient with large B-cell lymphoma.Blood advances2021name in title: axicabtagene ciloleucel
PMID 34515338Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.The Cochrane database of systematic reviews2021cited by trial NCT02348216
PMID 34590303Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.British journal of haematology2021name in title: axicabtagene ciloleucel
PMID 34697175Pembrolizumab-induced Remission After Failure of Axicabtagene Ciloleucel: Case Report and Literature Review.In vivo (Athens, Greece)2021name in title: axicabtagene ciloleucel
PMID 35845220Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report.EJHaem2021name in abstract: axicabtagene ciloleucel
PMID 31725923Axicabtagene ciloleucel for CD19+ plasmablastic lymphoma.American journal of hematology2020name in title: axicabtagene ciloleucel
PMID 31959992Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.Nature medicine2020name in abstract: axicabtagene ciloleucel
PMID 31973908Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma.American journal of kidney diseases : the official journal of the National Kidney Foundation2020name in abstract: axicabtagene ciloleucel
PMID 32001800Fatal Mycobacterium abscessus in a recipient of axicabtagene ciloleucel CAR-T: beware of T cells.Bone marrow transplantation2020name in title: axicabtagene ciloleucel
PMID 32181801Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.Blood2020name in title: axicabtagene ciloleucel
PMID 32242358KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.The New England journal of medicine2020cited by trial NCT02601313
PMID 32271899Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.Blood advances2020name in abstract: axicabtagene ciloleucel
PMID 32667831Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2020name in title: axicabtagene ciloleucel
PMID 32669372Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.Clinical cancer research : an official journal of the American Association for Cancer Research2020name in title: axicabtagene ciloleucel
PMID 32744738Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center.American journal of hematology2020name in abstract: axicabtagene ciloleucel
PMID 32777012Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.JAMA neurology2020name in abstract: axicabtagene ciloleucel
PMID 32998963Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research2020cited by trial NCT04071366
PMID 33020644Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas.Nature medicine2020name in abstract: axicabtagene ciloleucel
PMID 33021872Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2020name in abstract: axicabtagene ciloleucel
PMID 33035333Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma.Blood advances2020cited by trial NCT02348216
PMID 33067318Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2.Journal for immunotherapy of cancer2020cited by trial NCT02601313
PMID 30413526FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-cell Lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research2019name in title: axicabtagene ciloleucel
PMID 30518502Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.The Lancet. Oncology2019cited by trial NCT02348216
PMID 31211433Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells.American journal of hematology2019name in title: axicabtagene ciloleucel
PMID 31685159Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.Mayo Clinic proceedings2019name in title: axicabtagene ciloleucel
PMID 28129122Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.Molecular therapy : the journal of the American Society of Gene Therapy2017name in title: KTE-C19
PMID 29226797Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.The New England journal of medicine2017cited by trial NCT02348216

Other papers

Preclinical studies, reviews and other papers that name it, newest 100 shown.

PubMedTitleJournalYearLinked by
PMID 39410883Neurotoxicity associated with chimeric antigen receptor T-cell therapy: a real-world study leveraging the FDA Adverse Event Reporting System.Expert opinion on drug safety2026name in abstract: axicabtagene ciloleucel
PMID 40373976Health and Economic Impact of Vein-to-Vein Time in CAR T-Cell Therapy in the Second-Line Treatment of Relapsed/Refractory Large B-Cell Lymphoma: A US Cost-Effectiveness Analysis.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 40637750Safety and efficacy of bridging radiation therapy prior to CD19 CAR T for non-Hodgkin lymphoma: a systematic review and meta-analysis.Haematologica2026name in abstract: axicabtagene ciloleucel
PMID 40953732Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 40968610Effectiveness of CAR-T Cell Therapies for Relapsed/Refractory Follicular Lymphoma: An External Control Arm Study.Cancer research and treatment2026name in abstract: axicabtagene ciloleucel
PMID 41138816Who Is Eligible for Chimeric Antigen Receptor T Cell Therapy? Expert Perspectives on Overcoming Referral Barriers.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41143460A Pharmacologic Model Predicts that Tumor Debulking Improves CAR T-cell Efficacy in Large B-cell Lymphoma.Blood cancer discovery2026name in abstract: axicabtagene ciloleucel
PMID 41183747Comparative Analysis of Lymphodepletion Regimens in CART-19 Treatment for Relapsed/Refractory Diffuse Large B Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41247641Low reticulocyte count at infusion is a risk factor for high-grade cytokine release syndrome in chimeric antigen receptor T cell therapy.International journal of hematology2026name in abstract: axicabtagene ciloleucel
PMID 41263639Beyond Expansion: Tumor Debulking as Key to Improving CAR T-Cell Potential in Lymphoma.Blood cancer discovery2026name in abstract: axicabtagene ciloleucel
PMID 41345759Comparative Economic Evaluations of CAR-T Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review.PharmacoEconomics2026name in abstract: axicabtagene ciloleucel
PMID 41355413Short-term costs associated with outpatient use of axicabtagene ciloleucel in second-line and above relapsed/refractory large B-cell lymphoma based on the zuma-24 clinical trial.Leukemia & lymphoma2026name in title: axicabtagene ciloleucel
PMID 41391508Immune Effector Cell-Associated HLH-Like Syndrome (IEC-HS) in CAR-T and TCE-Treated Myeloma and B-Cell Malignancies: Insights from a Pharmacovigilance Study.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41396346Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.PharmacoEconomics - open2026name in abstract: axicabtagene ciloleucel
PMID 41448297Chimeric antigen receptor T-cell therapy and immune effector cell-associated neurotoxicity syndrome: A meta-analysis.Critical reviews in oncology/hematology2026name in abstract: axicabtagene ciloleucel
PMID 41467613Axicabtagene ciloleucel demonstrates superior outcomes over historically available treatments in relapsed/refractory follicular lymphoma: 5-year comparative analysis between ZUMA-5 and SCHOLAR-5.Leukemia & lymphoma2026name in title: axicabtagene ciloleucel
PMID 41483380Safety and effectiveness of lisocabtagene maraleucel following PD-1 blockade in relapsed or refractory PMBCL.International journal of hematology2026name in abstract: axicabtagene ciloleucel
PMID 41492445Efficacy and safety of chimeric antigen receptor T-cell therapy in relapsed/refractory large B-cell lymphoma: a systematic review and meta-analysis.Therapeutic advances in hematology2026name in abstract: axicabtagene ciloleucel
PMID 41525947Impact of Complete Response on Long-Term Survival in Patients with Relapsed or Refractory Large B-cell Lymphoma: A Center for International Blood and Marrow Transplant Research Prospective Study and Systematic Literature Review/Meta-Analysis.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41529329Impact of CD5 expression on outcomes for chimeric antigen receptor-T cell therapy in relapsed and refractory diffuse large B-cell lymphoma.Cytotherapy2026name in abstract: axicabtagene ciloleucel
PMID 41546434Brain Microstructural Damage as Potential Biomarker of Immune Cell-Associated Neurotoxicity Syndrome.Journal of neuroimaging : official journal of the American Society of Neuroimaging2026name in abstract: axicabtagene ciloleucel
PMID 41555654Single-centre analysis of prophylactic dexamethasone on the incidence and severity of cytokine release syndrome and immune effector cell-associated neurotoxicity in patients receiving axicabtagene ciloleucel.British journal of haematology2026name in title: axicabtagene ciloleucel
PMID 41582602Microbiome-Based Modeling of CAR-T Therapy Response in Lymphoma: Insights From Shotgun Metagenomics Sequencing.European journal of haematology2026name in abstract: axicabtagene ciloleucel
PMID 41596518Apheresis CD8+CCR7+CD45RA- T-Cells as a Novel Biomarker Associated with CAR T-Cell Kinetics and Clinical Outcome.International journal of molecular sciences2026name in abstract: axicabtagene ciloleucel
PMID 41676895ICANS mitigation in high-risk elderly patients treated with CD28 co-stimulatory anti-CD19 CAR-T cells using a standardization protocol: a pilot study.Haematologica2026name in abstract: axicabtagene ciloleucel
PMID 41698482Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41743266Outcomes of second-line axicabtagene ciloleucel for large B-cell lymphoma in the UK.HemaSphere2026name in title: axicabtagene ciloleucel
PMID 41744849Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada.Current oncology (Toronto, Ont.)2026name in title: axicabtagene ciloleucel
PMID 41748023Association Between Patient-Reported Outcomes Prior to Chimeric Antigen Receptor (CAR) T-Cell Therapy and Clinical Outcomes.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41762956Low reticulocyte count at infusion is a risk factor for ICANS in CAR-T cell therapy.Cytotherapy2026name in abstract: axicabtagene ciloleucel
PMID 41774434A new era for transplant-ineligible R/R LBCL patients: what's changing?Leukemia & lymphoma2026name in abstract: axicabtagene ciloleucel
PMID 41777657Advancing access to CAR T-cell therapy: insights and real-world experience from a community oncology practice.Frontiers in oncology2026name in abstract: axi-cel
PMID 41855506Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.Blood advances2026name in title: axicabtagene ciloleucel
PMID 41857785A global multidimensional analysis of the chimeric antigen receptor T-cell therapy clinical trial landscape and development trends.Biomarker research2026name in abstract: axicabtagene ciloleucel
PMID 41866225Spinal cord disease following CAR T-cell therapy with axicabtagene ciloleucel in a patient with high-grade B-cell lymphoma.Leukemia & lymphoma2026name in title: axicabtagene ciloleucel
PMID 41867486Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomas.Blood neoplasia2026name in abstract: axicabtagene ciloleucel
PMID 41891043Cell-free RNA Signatures Derived from the Tumor Microenvironment Predict Outcomes of CAR-T Therapy in Large B Cell Lymphoma.medRxiv : the preprint server for health sciences2026name in abstract: axicabtagene ciloleucel
PMID 41894687Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma.Blood advances2026name in title: axi-cel
PMID 41923554Circulating CAR T-Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B-Cell Lymphomas and Its Association to Treatment Outcome.European journal of haematology2026name in title: axicabtagene ciloleucel
PMID 41935576Neurotoxicity in Older Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy: A Multicenter Study.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 41964291Impaired hematopoiesis affects apheresis and CAR T-cell product composition and treatment response.Transfusion2026name in abstract: axi-cel
PMID 41968224Real-world outcomes of chimeric antigen receptor T-cell therapy with pembrolizumab as holding and/or bridging therapy in relapsed/refractory primary mediastinal large B-cell lymphoma.International journal of clinical oncology2026name in abstract: axicabtagene ciloleucel
PMID 41979680Distinct cellular signatures in aplastic and intermittent phenotypes of immune effector cell-associated hematotoxicity.Annals of hematology2026name in abstract: axicabtagene ciloleucel
PMID 42018609Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis.Blood advances2026name in abstract: axicabtagene ciloleucel
PMID 42028025Longitudinal ctDNA tracking by low-pass whole-genome sequencing predicts CAR-T outcomes in B-cell lymphomas.iScience2026name in abstract: axicabtagene ciloleucel
PMID 42038359Clinical implementation of a one-step no-wash flow cytometry method allows for real-time monitoring of patients treated with autologous CAR-T cells.Frontiers in oncology2026name in abstract: axicabtagene ciloleucel
PMID 42052989Unraveling the care pathway for CAR T-cell therapy in large B-cell lymphoma: insights from a nationwide study in France (2018-2023).Leukemia & lymphoma2026name in abstract: axicabtagene ciloleucel
PMID 42086512Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.American journal of hematology2026name in abstract: axicabtagene ciloleucel
PMID 42099680Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.HemaSphere2026name in abstract: axicabtagene ciloleucel
PMID 42101810Economic Evaluation of Axicabtagene Ciloleucel as a Second-Line Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in South Korea: A Cost-Utility Analysis Based on the ZUMA-7 Trial.Clinical drug investigation2026name in title: axicabtagene ciloleucel
PMID 42112708Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.Cancer immunology research2026name in abstract: axicabtagene ciloleucel
PMID 42118449T-cell fitness, metabolic tumor volume, and serum LDH levels are associated with response to axicabtagene ciloleucel.International journal of hematology2026name in title: axicabtagene ciloleucel
PMID 42119568Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.European journal of haematology2026name in abstract: axicabtagene ciloleucel
PMID 42137294Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies.Molecular therapy. Advances2026name in title: axicabtagene ciloleucel
PMID 42138782Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma.Advances in therapy2026name in title: axicabtagene ciloleucel
PMID 42140929Naïve CD4+ T-cells and disease status at CART infusion correlate with clinical outcomes in real-world large B-cell lymphoma patients receiving second-line CAR T therapy.Nature communications2026name in abstract: axicabtagene ciloleucel
PMID 42157590Persistent CAR-T signal in delayed immune effector cell-associated enterocolitis following axicabtagene ciloleucel.Leukemia & lymphoma2026name in title: axicabtagene ciloleucel
PMID 42169662Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.Hematology/oncology and stem cell therapy2026name in abstract: axicabtagene ciloleucel
PMID 42173255Prolonged Cytokine Release Syndrome is Associated with Hypofibrinogenemia after CD19-Directed CAR T-Cell Therapy in Adult Patients with Relapsed/Refractory Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 42251173Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.Bone marrow transplantation2026name in abstract: axicabtagene ciloleucel
PMID 42265975Beyond Chemoimmunotherapy: Emerging Cellular and Targeted Therapies in Transformed Follicular Lymphoma: A Scoping Review.Cancer control : journal of the Moffitt Cancer Center2026name in abstract: axicabtagene ciloleucel
PMID 42269079Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma.Blood advances2026name in abstract: axicabtagene ciloleucel
PMID 42279369Prophylactic Anakinra to Prevent Neurotoxicity After CAR T-Cell Therapy in Aggressive B-Cell Lymphomas: A Single-Center Real-World Experience.Cancers2026name in abstract: axicabtagene ciloleucel
PMID 42305450Comparative efficacy and safety of systemic therapies in transplant-eligible and ineligible relapsed/refractory large B-cell lymphoma: a Bayesian network meta-analysis.Translational cancer research2026name in abstract: axicabtagene ciloleucel
PMID 42329247Emerging T-Cell Engagers and Novel Immunotargets in Multiple Myeloma.Oncology (Williston Park, N.Y.)2026name in abstract: axicabtagene ciloleucel
PMID 42341926Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 42359427Durability Benchmarking of Contemporary Second-Line and Later Therapies for Relapsed or Refractory Follicular Lymphoma Using Reconstructed Individual Patient Data From Published Kaplan-Meier Curves.Cureus2026name in abstract: axicabtagene ciloleucel
PMID 42381271Immune effector cell-associated hematotoxicity following CAR-T cell therapies: insights from a large national database.Japanese journal of clinical oncology2026name in abstract: axicabtagene ciloleucel
PMID 42416925Identification of an optimal absolute lymphocyte count at leukapheresis in patients with lymphoma treated with CART.Blood immunology & cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 42428526Comparative efficacy and toxicity of Axicabtagene Ciloleucel versus Tisagenlecleucel in European patients with large B-cell lymphoma: a systematic review and meta-analysis.PeerJ2026name in title: axicabtagene ciloleucel
PMID 42453534Risk of thrombosis and bleeding following CAR T-cell therapy: Insights from the Dutch "Follow that CAR!" registry.HemaSphere2026name in abstract: axicabtagene ciloleucel
PMID 42471153Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine2026name in abstract: axicabtagene ciloleucel
PMID 42482164Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel.Clinical pharmacology and therapeutics2026name in title: axicabtagene ciloleucel
PMID 42489073TAFRO-like syndrome associated with long-term CAR-T cell persistence after axicabtagene ciloleucel therapy.Haematologica2026name in title: axicabtagene ciloleucel
PMID 42497245Genomic correlates of clinical CAR T cell activity.Science immunology2026name in abstract: axicabtagene ciloleucel
PMID 42507490Systematic literature review of clinical outcomes, health-related quality of life, and healthcare costs and resource use in relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel.Leukemia & lymphoma2026name in title: axicabtagene ciloleucel
PMID 42527721Follicular Lymphoma: Novel Therapies and Strategies for Optimal Therapeutic Sequencing.Current oncology reports2026name in abstract: axicabtagene ciloleucel
PMID 42537846Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome Following Axicabtagene Ciloleucel or Brexucabtagene Autoleucel Chimeric Antigen Receptor T-Cell Therapy: Center for International Blood and Marrow Transplant Research Data.Transplantation and cellular therapy2026name in title: axicabtagene ciloleucel
PMID 42556536Impact of Prior Bendamustine Exposure on Chimeric Antigen Receptor T-Cell Therapy Outcomes in Follicular Lymphoma.Transplantation and cellular therapy2026name in abstract: axicabtagene ciloleucel
PMID 42567965Effectiveness of anti-CD19 CAR T-cell therapy for high-grade B-cell lymphoma in Japan: a single-institution analysis.International journal of clinical oncology2026name in abstract: axicabtagene ciloleucel
PMID 42568509CD19 CAR-T cell therapy in large B-cell lymphoma: clinical evidence, resistance, toxicity, and precision strategies.Frontiers in immunology2026name in abstract: axicabtagene ciloleucel
PMID 42596901Impact on health outcomes of treating all eligible large B-cell lymphoma patients with axicabtagene ciloleucel in Portugal - A modeling approach.Journal of medical economics2026name in title: axicabtagene ciloleucel
PMID 42600565Shortened axi-cel manufacturing drives rapid in vivo expansion and shifts the acute toxicity profile in R/R LBCL.Blood advances2026name in title: axi-cel
PMID 42610412Improved progression free survival after axicabtagene ciloleucel compared to tisagenlecleucel, in patients aged >70 years with large B-cell lymphoma.Haematologica2026name in title: axicabtagene ciloleucel
PMID 42625595Post-CAR T-cell thyroid dysfunction: destructive thyroiditis identified through thyroid function monitoring in a single-center cohort.Frontiers in oncology2026name in abstract: axicabtagene ciloleucel
PMID 42640449Persistent parkinsonism with dopaminergic denervation following axicabtagene ciloleucel therapy for diffuse large B cell lymphoma: a case report.International journal of hematology2026name in title: axicabtagene ciloleucel
PMID 42645791Factors Associated with Increased Healthcare Utilization Within 30 and 90 Days Post-Discharge of CAR-T Cell Therapy in Patients with R/R LBCL.Hematology reports2026name in abstract: axicabtagene ciloleucel
PMID 42648741Implementation and use of risk minimization control tools in the EU: A multistakeholder survey.British journal of clinical pharmacology2026name in abstract: Yescarta
PMID 42660975Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy.Leukemia2026name in title: axi-cel
PMID 42663433InflaMix Predicts Severe CRS, ICU Admission, and Progression-Free Survival After CAR-T Therapy in LBCL.European journal of haematology2026name in abstract: axi-cel
PMID 42671910Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma.Blood cancer discovery2026name in abstract: axicabtagene ciloleucel
PMID 42686451In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed/Refractory Large B-Cell Lymphoma.Clinical lymphoma, myeloma & leukemia2026name in title: axicabtagene ciloleucel
PMID 42704001Dynamic risk stratification using early CAR-T expansion in R/R LBCL treated with axicabtagene ciloleucel.British journal of haematology2026name in title: axicabtagene ciloleucel
PMID 42709238Age as a moderator of neurocognitive performance in patients with large B-cell lymphoma treated with axicabtagene ciloleucel.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026name in title: axicabtagene ciloleucel
PMID 42726020Reusable Pipeline for Converting Real-World Lymphoma Registry Data to CDISC Standards: Implementation and Validation Using Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence.JCO clinical cancer informatics2026name in abstract: axicabtagene ciloleucel
PMID 42774885Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.HemaSphere2026name in title: axicabtagene ciloleucel
PMID 42777835Host immune biomarkers associated with infection risk after CAR T-cell therapy.The Journal of infection2026name in abstract: axicabtagene ciloleucel
PMID 42800585Real-World Comparison of Axicabtagene Ciloleucel and Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: A Target Trial Emulation.Transplantation and cellular therapy2026name in title: axicabtagene ciloleucel
PMID 42801949Prophylaxis with Dexamethasone or Anakinra in Patients with High-Risk Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.Transplantation and cellular therapy2026name in title: axicabtagene ciloleucel
PMID 42807827Integrating new and "old" cellular therapies in the evolving landscape of relapsed or refractory large B-cell lymphoma.Frontiers in oncology2026name in abstract: axi-cel

NIH grants

ProjectTitleOrganisationPIYearsLinked by
K08CA267307Determinants of Resistance to Engineered T-cell Therapies Targeting CD19 in LymphomaBECKMAN RESEARCH INSTITUTE/CITY OF HOPESWORDER, BRIAN2023–2026name in abstract: axicabtagene ciloleucel
P30CA016520Pediatric Oncology ProgramUNIVERSITY OF PENNSYLVANIAGRUPP, STEPHAN A.2021–2026name in abstract: axicabtagene ciloleucel
P30CA016672Stem Cell Biology & Cellular Therapy ProgramUNIVERSITY OF TX MD ANDERSON CAN CTRSHPALL, ELIZABETH J2019–2026name in abstract: axicabtagene ciloleucel
R01CA309280Engineering CD19 mimotopes for enhancing and repurposing CD19-CAR T against hematological malignancies and solid tumorsCHILDREN'S HOSP OF PHILADELPHIAMA, LEYUAN2026–2026name in abstract: Yescarta
R37CA250661Harnessing the thymus for long-term tumor control with hematopoietic stem cell-derived naive CAR T cellsHACKENSACK UNIVERSITY MEDICAL CENTERZAKRZEWSKI, JOHANNES2022–2026name in abstract: Yescarta
UG1HL108987Blood and Marrow Transplant Clinical Trials Network (BMT CTN) - Core Clinical Centers - UG1H. LEE MOFFITT CANCER CTR & RES INSTPIDALA, JOSEPH A2024–2026name in abstract: axicabtagene ciloleucel
UG1HL109137Phase III, Multicenter, Randomized, Double-Blind Study of Duvelisib as Cytokine Release Syndrome Prophylaxis in Patients with Large Cell or Mantle Cell Lymphoma Undergoing CAR T-Cell TherapiesWASHINGTON UNIVERSITYPUSIC, ISKRA2024–2026name in abstract: axicabtagene ciloleucel
R01CA252940Efficacy and immune effects of anakinra prophylaxis for neurologic toxicity and cytokine release syndrome in patients with lymphoma receiving axicabtagene ciloleucelMASSACHUSETTS GENERAL HOSPITALMAUS, MARCELA VALDERRAMA2020–2024name in title: axicabtagene ciloleucel
R21CA259694Targeting Myeloid Cells to Mitigate Immune Effector Cell-Associated Neurotoxicity Syndrome in Large B-cell LymphomaUNIVERSITY OF TX MD ANDERSON CAN CTRSTRATI, PAOLO2021–2021name in abstract: axi-cel

Notes

Gammaretroviral anti-CD19 (FMC63) CD28 CAR from NCI Surgery Branch, licensed to Kite. Same CAR as brexucabtagene autoleucel; different manufacturing.

How to cite

axicabtagene ciloleucel (AXP000014.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000014.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.